Eva L. Feldman, M.D, Ph.D. Russell N. DeJong Professor of Neurology, Director of the ALS Clinic, Director of the JDRF Center for the Study of Complications in Diabetes, Director of the Program for Neurology Research and Discovery and Director of the A. Alfred Taubman Medical Research Institute. Dr. Feldman completed both her medical degree and Ph.D. degree (Neuroscience) at the University of Michigan. She completed a residency in neurology at Johns Hopkins University, and a neuromuscular fellowship at the University of Michigan.
In addition to running an active clinical practice at the University of Michigan, Dr. Feldman directs a team of 30 scientists who collaborate to understand and find new treatments for a wide variety of neurological diseases, including ALS, diabetic neuropathy, Alzheimer's disease, and muscular dystrophies. She is the author of more than 220 articles, 50 book chapters and 2 books. She is the Principal Investigator of 4 major National Institutes of Health research grants, 3 private foundation grants and 5 clinical trials focused on understanding and treating neurological disorders, with an emphasis on ALS and diabetic neuropathy. She developed a clinical screening instrument for the rapid diagnosis of diabetic neuropathy, which is currently being used worldwide. Dr. Feldman is also on the forefront of applying stem cell research to human disease. In September 2010, she received approval from the F.D.A. for the first human clinical trial of a stem cell treatment for ALS. She is President-elect of the American Neurological Association and recent Past President of the Peripheral Nerve Society. She has received many honors including the Early Distinguished Career Award from the University of Michigan, several scientific achievement awards in the field of diabetes and was elected to the Johns Hopkins Society of Scholars. Additionally, she has been listed in Best Doctors in America for 10 consecutive years.
Among Dr. Feldman's greatest accomplishments is her training of both scientists and neurologists. Eight scientists have received their Ph.D. degrees under her, she has trained 40 postdoctoral fellows in her laboratory to become neuroscientists, and 36 neurologists have trained under her to specialize in the understanding and treatment of neuromuscular diseases, with an emphasis on ALS.